Drug Development

Area of Science:

• Neuroscience
• Pharmacology
• Animal Models of Disease

Background:

• Dementia presents complex, heterogeneous pathologies challenging translational research.
• Accurate assessment of cognitive domains (memory, attention, executive function) in animal models is difficult.
• Multi-domain cognitive assessments are vital for understanding diverse dementia-related impairments.

Purpose of the Study:

• To evaluate a scopolamine-induced mouse model for cognitive impairments relevant to dementia.
• To assess the efficacy of donepezil in reversing these induced cognitive deficits.
• To investigate domain-specific and dose-dependent effects of treatment within a multi-task battery.

Main Methods:

• Male C57BL/6 mice received scopolamine to induce cognitive deficits, followed by donepezil treatment.
• Cognitive functions were assessed using a touchscreen operant system.
• Tasks included Visual Discrimination (VD), 5-Choice Serial Reaction Time Task (5-CSRTT), Fixed/Progressive Ratio (FR/PR), and Paired Associate Learning (PAL).

Main Results:

• Scopolamine impaired performance in VD and PAL tasks; donepezil reversed VD deficits.
• Donepezil (3 mg/kg) reversed scopolamine-induced deficits in 5-CSRTT, showing a dose-dependent effect.
• Scopolamine altered motivation in FR/PR, an effect not reversed by donepezil, indicating model limitations.

Conclusions:

• The scopolamine model shows domain-specific deficits and variable treatment responses.
• Task and dose optimization is needed to improve model reliability for dementia research.
• A comprehensive multi-domain battery could serve as a robust preclinical platform for therapeutic evaluation.